|
US6143746A
(en)
*
|
1994-01-21 |
2000-11-07 |
Icos Corporation |
Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
|
|
GB9514465D0
(en)
*
|
1995-07-14 |
1995-09-13 |
Glaxo Lab Sa |
Chemical compounds
|
|
GB9511220D0
(en)
*
|
1995-06-02 |
1995-07-26 |
Glaxo Group Ltd |
Solid dispersions
|
|
US6046216A
(en)
|
1995-06-07 |
2000-04-04 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
|
|
US6200980B1
(en)
|
1995-06-07 |
2001-03-13 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl purinone derivatives
|
|
US5874440A
(en)
|
1995-06-07 |
1999-02-23 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
|
|
US6262059B1
(en)
|
1995-06-07 |
2001-07-17 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with quinazoline derivatives
|
|
US6232312B1
(en)
|
1995-06-07 |
2001-05-15 |
Cell Pathways, Inc. |
Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
|
|
US6060477A
(en)
|
1995-06-07 |
2000-05-09 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
|
|
GB9514473D0
(en)
*
|
1995-07-14 |
1995-09-13 |
Glaxo Lab Sa |
Chemical compounds
|
|
GB9514464D0
(en)
*
|
1995-07-14 |
1995-09-13 |
Glaxo Lab Sa |
Medicaments
|
|
CZ358598A3
(cs)
|
1996-05-10 |
1999-03-17 |
Icos Corporation |
Karbolinové deriváty
|
|
US5958926A
(en)
*
|
1996-11-01 |
1999-09-28 |
Nitromed, Inc. |
Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
|
|
US6331543B1
(en)
*
|
1996-11-01 |
2001-12-18 |
Nitromed, Inc. |
Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
|
|
US6071934A
(en)
|
1997-03-25 |
2000-06-06 |
Cell Pathways, Inc. |
Indenyl hydroxamic acids, (hydroxy) ureas and urethanes for treating patients with precancerous lesions
|
|
AU756136B2
(en)
|
1997-06-23 |
2003-01-02 |
Queen's University At Kingston |
Microdose therapy
|
|
US6403597B1
(en)
*
|
1997-10-28 |
2002-06-11 |
Vivus, Inc. |
Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
|
|
US6046199A
(en)
*
|
1998-01-14 |
2000-04-04 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
|
|
US6410584B1
(en)
|
1998-01-14 |
2002-06-25 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells with indole derivatives
|
|
US6268372B1
(en)
|
1998-09-11 |
2001-07-31 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
|
|
US6326379B1
(en)
|
1998-09-16 |
2001-12-04 |
Bristol-Myers Squibb Co. |
Fused pyridine inhibitors of cGMP phosphodiesterase
|
|
IL132406A0
(en)
*
|
1998-10-21 |
2001-03-19 |
Pfizer Prod Inc |
Treatment of bph with cgmp elevators
|
|
US6133271A
(en)
|
1998-11-19 |
2000-10-17 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
|
|
US6187779B1
(en)
|
1998-11-20 |
2001-02-13 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
|
|
US6211220B1
(en)
|
1998-11-23 |
2001-04-03 |
Cell Pathways, Inc. |
Method for treating neoplasia with amino or pyridylamino cyclobutene derivatives
|
|
US6348032B1
(en)
|
1998-11-23 |
2002-02-19 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with benzimidazole derivatives
|
|
US6420410B1
(en)
|
1998-11-24 |
2002-07-16 |
Cell Pathways, Inc. |
Method for treating neoplasia by exposure to N,N′-substituted benzimidazol-2-ones
|
|
US6486155B1
(en)
|
1998-11-24 |
2002-11-26 |
Cell Pathways Inc |
Method of inhibiting neoplastic cells with isoquinoline derivatives
|
|
US6211177B1
(en)
|
1998-11-24 |
2001-04-03 |
Cell Pathways, Inc. |
Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
|
|
US6358992B1
(en)
|
1998-11-25 |
2002-03-19 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with indole derivatives
|
|
CA2367138C
(en)
|
1999-03-24 |
2010-10-05 |
Alejandro M. S. Mayer |
Anti-inflammatory uses of manzamines
|
|
MXPA00003997A
(es)
*
|
1999-04-30 |
2002-03-08 |
Lilly Icos Llc |
Articulos de fabricacion.
|
|
US6451807B1
(en)
|
1999-04-30 |
2002-09-17 |
Lilly Icos, Llc. |
Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
|
|
US6943166B1
(en)
*
|
1999-04-30 |
2005-09-13 |
Lilly Icos Llc. |
Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
|
|
US7235625B2
(en)
|
1999-06-29 |
2007-06-26 |
Palatin Technologies, Inc. |
Multiple agent therapy for sexual dysfunction
|
|
WO2001008686A1
(en)
*
|
1999-08-03 |
2001-02-08 |
Lilly Icos Llc |
Beta-carboline pharmaceutical compositions
|
|
US6821975B1
(en)
|
1999-08-03 |
2004-11-23 |
Lilly Icos Llc |
Beta-carboline drug products
|
|
JP2003511452A
(ja)
|
1999-10-11 |
2003-03-25 |
ファイザー・インク |
ホスホジエステラーゼ阻害剤としての５−（２−置換−５−ヘテロシクリルスルホニルピリド−３−イル）−ジヒドロピラゾロ［４，３−ｄ］ピリミジン−７−オン
|
|
TW200400821A
(en)
*
|
1999-11-02 |
2004-01-16 |
Pfizer |
Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
|
|
US6562830B1
(en)
|
1999-11-09 |
2003-05-13 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl quinazolinone derivatives
|
|
US6376489B1
(en)
*
|
1999-12-23 |
2002-04-23 |
Icos Corporation |
Cyclic AMP-specific phosphodiesterase inhibitors
|
|
US20020013327A1
(en)
*
|
2000-04-18 |
2002-01-31 |
Lee Andrew G. |
Compositions and methods for treating female sexual dysfunction
|
|
AU2001255849B8
(en)
|
2000-04-19 |
2006-04-27 |
Lilly Icos, Llc. |
PDE-V inhibitors for treatment of Parkinson's Disease
|
|
UA74826C2
(en)
|
2000-05-17 |
2006-02-15 |
Ortho Mcneil Pharm Inc |
?-carboline derivatives as phosphodiesterase inhibitors
|
|
UA72611C2
(uk)
*
|
2000-05-17 |
2005-03-15 |
Орто-Макнейл Фармацевтикал, Інк. |
Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
|
|
CA2411008C
(en)
|
2000-06-07 |
2006-04-11 |
Lilly Icos Llc |
Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
|
|
AU2001263278A1
(en)
|
2000-06-23 |
2002-01-08 |
Lilly Icos Llc |
Cyclic gmp-specific phosphodiesterase inhibitors
|
|
JP4169149B2
(ja)
*
|
2000-06-23 |
2008-10-22 |
リリー アイコス リミテッド ライアビリティ カンパニー |
化学的化合物
|
|
CA2413510C
(en)
*
|
2000-06-26 |
2007-12-11 |
Lilly Icos Llc |
Condensed pyrazindione derivatives
|
|
MXPA03000688A
(es)
*
|
2000-07-24 |
2004-11-01 |
Bayer Cropscience Ag |
Bifenilcarboxiamidas.
|
|
US7034027B2
(en)
*
|
2000-08-02 |
2006-04-25 |
Lilly Icos Llc |
Fused heterocyclic derivatives as phosphodiesterase inhibitors
|
|
US20040092494A9
(en)
*
|
2000-08-30 |
2004-05-13 |
Dudley Robert E. |
Method of increasing testosterone and related steroid concentrations in women
|
|
US6503894B1
(en)
|
2000-08-30 |
2003-01-07 |
Unimed Pharmaceuticals, Inc. |
Pharmaceutical composition and method for treating hypogonadism
|
|
US6821978B2
(en)
|
2000-09-19 |
2004-11-23 |
Schering Corporation |
Xanthine phosphodiesterase V inhibitors
|
|
AU2001292698A1
(en)
*
|
2000-10-02 |
2002-04-15 |
Lilly Icos Llc |
Hexahydropyrazino `1'2' : 1, 6!- pyrido `3, 4-b! indole-1, 4-dione derivatives for the treatment of cardiovascular disorders and erectile disfunction
|
|
CA2423308A1
(en)
|
2000-10-02 |
2002-04-11 |
Lilly Icos Llc |
Condensed pyridoindole derivatives
|
|
US6548508B2
(en)
|
2000-10-20 |
2003-04-15 |
Pfizer, Inc. |
Use of PDE V inhibitors for improved fecundity in mammals
|
|
EP1211313A3
(en)
*
|
2000-11-01 |
2003-04-23 |
Pfizer Limited |
Modulation of PDE11A activity
|
|
US6828473B2
(en)
|
2000-11-01 |
2004-12-07 |
Pfizer Inc. |
Modulation of PDE11A activity
|
|
ES2271080T3
(es)
*
|
2000-11-06 |
2007-04-16 |
Lilly Icos Llc |
Derivados de indol como inhibidores de pde5.
|
|
US7115621B2
(en)
*
|
2001-04-25 |
2006-10-03 |
Lilly Icos Llc |
Chemical compounds
|
|
FR2824829B1
(fr)
*
|
2001-05-16 |
2005-06-03 |
Macef |
Nouveaux derives de dihydroimidazo [5,1-a]-beta-carboline, leur procede de preparation et leur application a titre de medicament
|
|
US6992192B2
(en)
|
2001-06-05 |
2006-01-31 |
Lilly Icos Llc. |
Carboline derivatives as PDE5 inhibitors
|
|
MXPA03011080A
(es)
*
|
2001-06-05 |
2004-07-08 |
Lilly Icos Llc |
Compuestos tetraciclicos como inhibidores de pde5.
|
|
US7098209B2
(en)
|
2001-06-05 |
2006-08-29 |
Lilly Icos Llc |
Pyrazino [1'2':1,6 ] pyrido [3, 4-b] indole-1,4-dione derivatives
|
|
ATE335742T1
(de)
*
|
2001-06-21 |
2006-09-15 |
Lilly Icos Llc |
Carbolinderivate als pdev inhibitoren
|
|
US10675280B2
(en)
|
2001-10-20 |
2020-06-09 |
Sprout Pharmaceuticals, Inc. |
Treating sexual desire disorders with flibanserin
|
|
UA78974C2
(en)
|
2001-10-20 |
2007-05-10 |
Boehringer Ingelheim Pharma |
Use of flibanserin for treating disorders of sexual desire
|
|
US6943171B2
(en)
*
|
2001-11-09 |
2005-09-13 |
Schering Corporation |
Polycyclic guanine derivative phosphodiesterase V inhibitors
|
|
ATE368040T1
(de)
*
|
2001-11-14 |
2007-08-15 |
Ortho Mcneil Pharmaceutical Co |
Substituierte tetrazyklische pyprolochinolonderivate als phosphodiesterase- inhibitoren
|
|
US6962940B2
(en)
|
2002-03-20 |
2005-11-08 |
Celgene Corporation |
(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
|
|
US7276529B2
(en)
|
2002-03-20 |
2007-10-02 |
Celgene Corporation |
Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
|
US7893101B2
(en)
|
2002-03-20 |
2011-02-22 |
Celgene Corporation |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
|
|
US7208516B2
(en)
|
2002-03-20 |
2007-04-24 |
Celgene Corporation |
Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
|
DE10220570A1
(de)
|
2002-05-08 |
2003-11-20 |
Bayer Ag |
Carbamat-substituierte Pyrazolopyridine
|
|
JP2005529927A
(ja)
*
|
2002-05-23 |
2005-10-06 |
ファイザー インコーポレイテッド |
新規な組み合わせ
|
|
EP1719772A1
(en)
|
2002-05-31 |
2006-11-08 |
Schering Corporation |
Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
|
|
GB0214784D0
(en)
*
|
2002-06-26 |
2002-08-07 |
Pfizer Ltd |
Novel combination
|
|
CN100430395C
(zh)
*
|
2002-07-31 |
2008-11-05 |
利利艾科斯有限公司 |
改进的皮克特-施彭格勒反应和由该反应制备得到的产物
|
|
GB0219961D0
(en)
|
2002-08-28 |
2002-10-02 |
Pfizer Ltd |
Oxytocin inhibitors
|
|
US7323462B2
(en)
|
2002-12-10 |
2008-01-29 |
Pfizer Inc. |
Morpholine dopamine agonists
|
|
PL377657A1
(pl)
|
2002-12-13 |
2006-02-06 |
Warner-Lambert Company Llc |
Ligand Ó-2-Ű do leczenia dolegliwości dolnych dróg moczowych
|
|
BRPI0409229A
(pt)
|
2003-04-01 |
2006-03-28 |
Applied Research Systems |
inibidores das fosfodiesterases na infertilidade
|
|
DK1620437T3
(da)
|
2003-04-29 |
2009-08-24 |
Pfizer Ltd |
5,7-diaminopyrazolo-4,3-d-pyrimidiner, der er anvendelige til behandling af hypertension
|
|
BRPI0410326A
(pt)
|
2003-05-22 |
2006-05-23 |
Altana Pharma Ag |
composição compreendendo um inibidor pde4 e inibidor pde5
|
|
DK1644021T3
(da)
|
2003-06-13 |
2012-10-29 |
Ironwood Pharmaceuticals Inc |
Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
|
|
EP1637521B1
(en)
|
2003-06-23 |
2013-06-19 |
Ono Pharmaceutical Co., Ltd. |
Novel tricyclic heterocycle compound
|
|
US7291640B2
(en)
|
2003-09-22 |
2007-11-06 |
Pfizer Inc. |
Substituted triazole derivatives as oxytocin antagonists
|
|
US7572799B2
(en)
|
2003-11-24 |
2009-08-11 |
Pfizer Inc |
Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
|
|
EP1699436A2
(en)
*
|
2003-12-12 |
2006-09-13 |
Myogen, Inc. |
Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
|
|
WO2005068464A2
(en)
*
|
2003-12-15 |
2005-07-28 |
Cadila Healthcare Limited |
Process for preparing tadalafil and its intermediates
|
|
BRPI0506994A
(pt)
|
2004-01-22 |
2007-07-03 |
Pfizer |
derivados de triazol que inibem a atividade antagonista da vasopressina
|
|
US7649002B2
(en)
|
2004-02-04 |
2010-01-19 |
Pfizer Inc |
(3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
|
|
WO2005092333A1
(en)
*
|
2004-03-22 |
2005-10-06 |
Myogen, Inc. |
(r)-enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
|
|
JP2007530563A
(ja)
*
|
2004-03-22 |
2007-11-01 |
ミオゲン インコーポレイティッド |
（ｓ）−エノキシモンスルホキシドおよびｐｄｅ−ｉｉｉ媒介疾患の治療におけるその使用
|
|
US7569572B2
(en)
|
2004-04-07 |
2009-08-04 |
Pfizer Inc |
Pyrazolo[4,3-D]pyrimidines
|
|
WO2005116030A1
(en)
*
|
2004-05-31 |
2005-12-08 |
Matrix Laboratories Ltd |
A process for the preparation of tadalafil
|
|
WO2006007213A1
(en)
*
|
2004-06-23 |
2006-01-19 |
Myogen, Inc. |
Enoximone formulations and their use in the treatment of pde-iii mediated diseases
|
|
AU2005277384B2
(en)
|
2004-08-17 |
2011-11-17 |
The Johns Hopkins University |
PDE5 inhibitor compositions and methods for treating cardiac indications
|
|
WO2006049986A1
(en)
*
|
2004-10-28 |
2006-05-11 |
Dr. Reddy's Laboratories Ltd. |
Polymorphic forms of tadalafil
|
|
KR20070072891A
(ko)
*
|
2004-11-02 |
2007-07-06 |
테바 파마슈티컬 인더스트리즈 리미티드 |
타달라필 결정형 및 이의 제조 방법
|
|
AR051780A1
(es)
*
|
2004-11-29 |
2007-02-07 |
Japan Tobacco Inc |
Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
|
|
EP1829874B1
(en)
|
2004-12-22 |
2014-02-12 |
Ono Pharmaceutical Co., Ltd. |
Tricyclic compound and use thereof
|
|
CA2596667A1
(en)
*
|
2005-02-25 |
2006-08-31 |
Teva Pharmaceutical Industries Ltd. |
Process of synthesizing tadalafil
|
|
WO2006091974A1
(en)
*
|
2005-02-25 |
2006-08-31 |
Teva Pharmaceutical Industries Ltd. |
Tadalafil having a large particle size and a process for preparation thereof
|
|
EP1851223A1
(en)
*
|
2005-02-25 |
2007-11-07 |
Teva Pharmaceutical Industries Ltd |
Process of purifying tadalafil
|
|
US20070088012A1
(en)
*
|
2005-04-08 |
2007-04-19 |
Woun Seo |
Method of treating or preventing type-2 diabetes
|
|
KR20070110941A
(ko)
*
|
2005-04-12 |
2007-11-20 |
테바 파마슈티컬 인더스트리즈 리미티드 |
타달라필 중간체의 제조 방법
|
|
AU2006237300B2
(en)
|
2005-04-19 |
2011-10-13 |
Takeda Gmbh |
Roflumilast for the treatment of pulmonary hypertension
|
|
US8506934B2
(en)
|
2005-04-29 |
2013-08-13 |
Robert I. Henkin |
Methods for detection of biological substances
|
|
BRPI0609225A2
(pt)
|
2005-05-12 |
2010-03-09 |
Pfizer |
formas cristalinas anidras de n-[1-(2-etoxietil)-5-(n-etil-n-metilamino)-7-(4-metilpiridi n-2-il-amino)-1h-pirazolo[4,3-d]pirimidina-3-carbonil] metanossulfonamida, composição farmacêutica compreendendo as mesmas e uso das mesmas
|
|
US20070010525A1
(en)
*
|
2005-06-27 |
2007-01-11 |
Meyer Jackson |
Method and compositions for modulating neuropeptide hormone secretion
|
|
JP2009502961A
(ja)
*
|
2005-07-29 |
2009-01-29 |
コンサート ファーマシューティカルズ インコーポレイテッド |
新規な医薬組成物
|
|
US7863274B2
(en)
*
|
2005-07-29 |
2011-01-04 |
Concert Pharmaceuticals Inc. |
Deuterium enriched analogues of tadalafil as PDE5 inhibitors
|
|
EP1912650B8
(en)
|
2005-08-03 |
2017-10-18 |
Sprout Pharmaceuticals, Inc. |
Use of flibanserin in the treatment of obesity
|
|
CA2620333A1
(en)
|
2005-08-26 |
2007-03-01 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation
|
|
EP2258357A3
(en)
|
2005-08-26 |
2011-04-06 |
Braincells, Inc. |
Neurogenesis with acetylcholinesterase inhibitor
|
|
CA2622200A1
(en)
*
|
2005-09-13 |
2007-03-22 |
Elan Pharma International, Limited |
Nanoparticulate tadalafil formulations
|
|
CA2624788C
(en)
|
2005-10-12 |
2011-04-19 |
Unimed Pharmaceuticals, Llc |
Improved testosterone gel and method of use
|
|
JP2009512711A
(ja)
|
2005-10-21 |
2009-03-26 |
ブレインセルス，インコーポレイティド |
Ｐｄｅ阻害による神経新生の調節
|
|
EP1945214A1
(en)
|
2005-10-29 |
2008-07-23 |
Boehringer Ingelheim International GmbH |
Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
|
|
US20070112017A1
(en)
|
2005-10-31 |
2007-05-17 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
|
WO2007100387A2
(en)
*
|
2005-11-03 |
2007-09-07 |
Dr. Reddy's Laboratories Ltd. |
Process for preparing tadalafil
|
|
TWI435729B
(zh)
|
2005-11-09 |
2014-05-01 |
Combinatorx Inc |
治療病症之方法，組合物及套組
|
|
US7202229B1
(en)
*
|
2005-12-30 |
2007-04-10 |
Alan James Group, Llc. |
Aspirin formulation for cardiovascular health
|
|
US7201929B1
(en)
*
|
2005-12-30 |
2007-04-10 |
Alan James Group, Llc. |
Aspirin formulation for cardiovascular health
|
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
|
EP1991212A1
(en)
*
|
2006-03-08 |
2008-11-19 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
WO2007110734A1
(en)
*
|
2006-03-24 |
2007-10-04 |
Glenmark Pharmaceuticals Limited |
Process for the preparation of tadalafil
|
|
US20080027072A1
(en)
*
|
2006-04-20 |
2008-01-31 |
Ampla Pharmaceuticals, Inc. |
Potentiation of MC4 receptor activity
|
|
US20100009983A1
(en)
*
|
2006-05-09 |
2010-01-14 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
|
CA2651862A1
(en)
*
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
|
EP2382975A3
(en)
|
2006-05-09 |
2012-02-29 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
|
US20090291958A1
(en)
*
|
2006-06-08 |
2009-11-26 |
Auspex Pharmaceuticals, Inc. |
Substituted PDE5 inhibitors
|
|
JP2009541443A
(ja)
|
2006-06-30 |
2009-11-26 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
尿失禁及び関連疾患の治療のためのフリバンセリン
|
|
BRPI0621852A2
(pt)
*
|
2006-07-07 |
2011-12-20 |
Teva Pharma |
compostos sólidos consistindo de tadalafil e pelo menos um veìculo
|
|
DK2046292T3
(da)
|
2006-07-21 |
2010-06-07 |
Novartis Ag |
Formuleringer for benzimidazolylpyridylethere
|
|
KR20090042967A
(ko)
|
2006-08-14 |
2009-05-04 |
베링거 인겔하임 인터내셔날 게엠베하 |
플리반세린 제형 및 이의 제조방법
|
|
CN104721168A
(zh)
|
2006-08-25 |
2015-06-24 |
贝林格尔·英格海姆国际有限公司 |
控制释放系统及其制造方法
|
|
AR062501A1
(es)
*
|
2006-08-29 |
2008-11-12 |
Actelion Pharmaceuticals Ltd |
Composiciones terapeuticas
|
|
JP2010502722A
(ja)
*
|
2006-09-08 |
2010-01-28 |
ブレインセルス，インコーポレイティド |
４−アシルアミノピリジン誘導体を含む組み合わせ
|
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
|
CA2663347A1
(en)
*
|
2006-09-19 |
2008-03-27 |
Braincells, Inc. |
Ppar mediated modulation of neurogenesis
|
|
ES2544724T3
(es)
|
2006-12-12 |
2015-09-03 |
Gilead Sciences, Inc. |
Composición para tratar una hipertensión pulmonar
|
|
US8293489B2
(en)
|
2007-01-31 |
2012-10-23 |
Henkin Robert I |
Methods for detection of biological substances
|
|
KR20130122023A
(ko)
|
2007-02-12 |
2013-11-06 |
디엠아이 바이오사이언시스 인코포레이티드 |
트라마돌의 부작용을 감소시키는 방법
|
|
CA2677690C
(en)
|
2007-02-12 |
2012-05-15 |
James V. Winkler |
Treatment of comorbid premature ejaculation and erectile dysfunction
|
|
WO2008103470A2
(en)
*
|
2007-02-21 |
2008-08-28 |
Trustees Of Columbia University In The City Of New York |
Oncogenic-ras-signal dependent lethal compounds
|
|
US20090098211A1
(en)
*
|
2007-04-25 |
2009-04-16 |
Ilan Zalit |
Solid dosage forms
|
|
FR2916200A1
(fr)
*
|
2007-05-18 |
2008-11-21 |
Fourtillan Snc |
Nouveaux derives des 1,2,3,4,6,7,12,12a-octahydro pyrazino[1',2':1,6]pyrido[3,4-b]indoles, leur preparation et leur utilisation en therapeutique
|
|
DE102007028869A1
(de)
*
|
2007-06-22 |
2008-12-24 |
Ratiopharm Gmbh |
Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
|
|
PT2170880E
(pt)
|
2007-06-29 |
2012-10-29 |
Ranbaxy Lab Ltd |
Processo para a preparação de intermediários de compostos tetracíclicos
|
|
EP2033962A1
(en)
*
|
2007-08-22 |
2009-03-11 |
4Sc Ag |
Tetracyclic indolopyridines as EG5 inhibitors
|
|
CL2008002693A1
(es)
|
2007-09-12 |
2009-10-16 |
Boehringer Ingelheim Int |
Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
|
|
WO2009091777A1
(en)
*
|
2008-01-15 |
2009-07-23 |
Forest Laboratories Holdings Limited |
Nebivolol in the treatment of sexual dysfunction
|
|
ITMI20080285A1
(it)
*
|
2008-02-22 |
2009-08-23 |
Endura Spa |
Procedimento per la preparazione di esteri di acidi tetraidro-1h-betacarbolin-3-carbossilici
|
|
EP2107059A1
(en)
|
2008-03-31 |
2009-10-07 |
LEK Pharmaceuticals D.D. |
Conversion of tryptophan into ß-carboline derivatives
|
|
PL385356A1
(pl)
|
2008-06-03 |
2009-12-07 |
Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna |
Sposób wytwarzania tadalafilu
|
|
US8580801B2
(en)
|
2008-07-23 |
2013-11-12 |
Robert I. Henkin |
Phosphodiesterase inhibitor treatment
|
|
EP2181997A1
(en)
|
2008-10-30 |
2010-05-05 |
Chemo Ibérica, S.A. |
A process for the preparation of tadalafil
|
|
DE102008063992A1
(de)
|
2008-12-19 |
2010-09-02 |
Lerner, Zinoviy, Dipl.-Ing. |
Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
|
|
EP2379076B1
(en)
|
2008-12-23 |
2014-11-12 |
The Trustees of Columbia University in the City of New York |
Phosphodiesterase inhibitors and uses thereof
|
|
WO2010099217A1
(en)
|
2009-02-25 |
2010-09-02 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
|
WO2010099323A1
(en)
|
2009-02-26 |
2010-09-02 |
Thar Pharmaceuticals, Inc. |
Crystalization of pharmaceutical compounds
|
|
GB0903493D0
(en)
|
2009-02-27 |
2009-04-08 |
Vantia Ltd |
New compounds
|
|
DE102009033396A1
(de)
|
2009-07-16 |
2011-01-20 |
Ratiopharm Gmbh |
Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
|
|
UY33041A
(es)
|
2009-11-27 |
2011-06-30 |
Bayer Schering Pharma Aktienegesellschaft |
Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
|
|
US10610528B2
(en)
|
2009-12-08 |
2020-04-07 |
Intelgenx Corp. |
Solid oral film dosage forms and methods for making same
|
|
US20110136815A1
(en)
|
2009-12-08 |
2011-06-09 |
Horst Zerbe |
Solid oral film dosage forms and methods for making same
|
|
CN102970965A
(zh)
|
2010-04-05 |
2013-03-13 |
Sk化学公司 |
含有pde5抑制剂的减少皮肤皱纹的合成物
|
|
DE102010021637A1
(de)
|
2010-05-26 |
2011-12-01 |
Bayer Schering Pharma Aktiengesellschaft |
Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
|
|
ES2627944T3
(es)
|
2010-10-15 |
2017-08-01 |
Gilead Sciences, Inc. |
Composiciones y métodos de tratamiento de hipertensión pulmonar
|
|
JP5816704B2
(ja)
|
2011-02-10 |
2015-11-18 |
インテルキム、ソシエダッド アノニマ |
テトラヒドロ−β−カルボリンから誘導される化合物を得る方法
|
|
RU2013141446A
(ru)
|
2011-02-10 |
2015-03-20 |
Синтон Бв |
Фармацевтическая композиция, содержащая тадалафил и циклодекстрин
|
|
WO2012107092A1
(en)
|
2011-02-10 |
2012-08-16 |
Synthon Bv |
Pharmaceutical composition comprising tadalafil and a cyclodextrin
|
|
WO2012107090A1
(en)
|
2011-02-10 |
2012-08-16 |
Synthon Bv |
Granulated composition comprising tadalafil and a disintegrant
|
|
US20120123124A1
(en)
*
|
2011-04-22 |
2012-05-17 |
Drug Process Licensing Associates, LLC |
Manufacturing process for Tadalafil from racemic or L-tryptophan
|
|
CN102180876B
(zh)
*
|
2011-05-28 |
2016-05-18 |
浙江华海药业股份有限公司 |
一种他达那非晶型i的制备方法
|
|
EP2535049A1
(en)
|
2011-06-17 |
2012-12-19 |
Proyecto de Biomedicina Cima, S.L. |
Tadalafil for the treatment of dementia
|
|
CN102367253B
(zh)
*
|
2011-09-20 |
2016-04-06 |
浙江华海药业股份有限公司 |
一种制备他达拉非晶型a的方法
|
|
WO2013067309A1
(en)
|
2011-11-04 |
2013-05-10 |
Xion Pharmaceutical Corporation |
Methods and compositions for oral administration of melanocortin receptor agonist compounds
|
|
EP2804603A1
(en)
|
2012-01-10 |
2014-11-26 |
President and Fellows of Harvard College |
Beta-cell replication promoting compounds and methods of their use
|
|
WO2013109738A1
(en)
|
2012-01-17 |
2013-07-25 |
The Trustees Of Columbia University In The City Of New York |
Novel phosphodiesterase inhibitors and uses thereof
|
|
WO2013109227A1
(en)
|
2012-01-18 |
2013-07-25 |
Mahmut Bilgic |
Pharmaceutical compositions comprising ceftibuten
|
|
WO2013109223A1
(en)
|
2012-01-18 |
2013-07-25 |
Mahmut Bilgic |
Particulate formulations of tadalafil in effervescent form
|
|
WO2014092661A1
(en)
|
2012-01-18 |
2014-06-19 |
Mahmut Bilgic |
Particulate formulations of tadalafil in effervescent form
|
|
US10092651B2
(en)
|
2012-02-28 |
2018-10-09 |
Seoul Pharma Co., Ltd. |
High-content fast dissolving film with masking of bitter taste comprising sildenafil as active ingredient
|
|
EP2903619B1
(en)
|
2012-10-05 |
2019-06-05 |
Robert I. Henkin |
Phosphodiesterase inhibitors for treating taste and smell disorders
|
|
ES2903151T3
(es)
|
2012-12-04 |
2022-03-31 |
Aribio Inc |
Composición que comprende inhibidor de fosfodiesterasa tipo 5 para inhibir la apoptosis de células nerviosas
|
|
KR101953735B1
(ko)
|
2012-12-14 |
2019-03-04 |
한미약품 주식회사 |
포스포다이에스터라제-5 억제제를 포함하는 츄정
|
|
ES2700989T3
(es)
|
2012-12-21 |
2019-02-20 |
Mayo Found Medical Education & Res |
Métodos y materiales para tratar estenosis de la válvula aórtica calcificada
|
|
HK1217488A1
(zh)
|
2013-02-21 |
2017-01-13 |
Adverio Pharma Gmbh |
{4,6-二氨基-2-[1-(2-氟苄基)-1h-吡唑并[3,4-b]吡啶-3-基]嘧啶-5-基}甲基氨基甲酸甲酯的形式
|
|
CN103232451A
(zh)
*
|
2013-05-14 |
2013-08-07 |
张家港威胜生物医药有限公司 |
一种他达那非的简易制备工艺
|
|
US10899756B2
(en)
|
2013-07-17 |
2021-01-26 |
The Trustees Of Columbia University In The City Of New York |
Phosphodiesterase inhibitors and uses thereof
|
|
US20160317542A1
(en)
|
2013-12-09 |
2016-11-03 |
Respira Therapeutics, Inc. |
Pde5 inhibitor powder formulations and methods relating thereto
|
|
WO2015126944A1
(en)
|
2014-02-18 |
2015-08-27 |
Henkin Robert I |
Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
|
|
AR099416A1
(es)
|
2014-02-28 |
2016-07-20 |
Lilly Co Eli |
Terapia combinada para la hipertensión resistente
|
|
US10300042B2
(en)
|
2014-06-23 |
2019-05-28 |
Celgene Corporation |
Apremilast for the treatment of a liver disease or a liver function abnormality
|
|
ES2784251T3
(es)
|
2014-06-30 |
2020-09-23 |
Montero Gida Sanayi Ve Ticaret As |
Formulaciones de disgregación por vía oral de tadalafilo
|
|
EP2962684A1
(en)
|
2014-06-30 |
2016-01-06 |
Sanovel Ilac Sanayi ve Ticaret A.S. |
Orally disintegrating formulations of tadalafil
|
|
CN104086546B
(zh)
*
|
2014-07-14 |
2016-08-17 |
福建广生堂药业股份有限公司 |
他达拉非的药用酸盐及其制备方法
|
|
EA035390B1
(ru)
|
2014-07-23 |
2020-06-05 |
КРКА, д.д., НОВО МЕСТО |
Совместный осадок тадалафила с фармацевтически приемлемыми эксципиентами, содержащая его фармацевтическая композиция и способ их получения
|
|
KR101645652B1
(ko)
|
2014-11-03 |
2016-08-08 |
(주)퓨젠바이오농업회사법인 |
세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 성기능개선용 조성물
|
|
KR102457316B1
(ko)
*
|
2015-06-26 |
2022-10-20 |
총킹 디캉 에릴 파마 씨오. 엘티디. |
새로운 5형포스포디에스테라아제 억제제 및 그 용도
|
|
CN105541840B
(zh)
*
|
2015-12-31 |
2017-12-05 |
湖南千金湘江药业股份有限公司 |
关键中间体及其合成方法和在制备他达拉非方面的应用
|
|
CN105541835B
(zh)
*
|
2015-12-31 |
2017-12-05 |
湖南千金湘江药业股份有限公司 |
顺式四氢咔啉中间体及其合成方法和在制备他达拉非方面的应用
|
|
CN110381951A
(zh)
|
2016-12-14 |
2019-10-25 |
瑞必治公司 |
用于治疗肺性高血压和其他肺病症的方法及组合物
|
|
CN106977516B
(zh)
*
|
2017-03-02 |
2019-06-18 |
山东裕欣药业有限公司 |
一种他达拉非的制备方法
|
|
SG11202110533RA
(en)
|
2019-04-10 |
2021-10-28 |
Mayo Found Medical Education & Res |
Methods and materials for gender-dependent treatment of cardiovascular dysfunction
|
|
RU2692764C1
(ru)
|
2019-04-26 |
2019-06-27 |
Общество с ограниченной ответственностью "Балтфарма" |
Способ получения тадалафила
|
|
CN111995658B
(zh)
*
|
2019-05-27 |
2022-08-02 |
首都医科大学 |
Ldv修饰的五环哌嗪二酮及其制备和应用
|
|
JP2022540866A
(ja)
|
2019-07-15 |
2022-09-20 |
バイオラブ・サヌス・ファーマセウティカ・エルティーディーエー． |
３－（ベンゾ［ｄ］［１，３］ジオキサゾール－５－イル）－７－（１－ヒドロキシプロパン－２－イル）－１－（１Ｈ－インドール－３－イル）－６，７－ジヒドロ－３Ｈ－オキサゾール［３，４－ａ］ピラジン－５，８－ジオン化合物の立体異性体およびその抗腫瘍剤およびホスホジエステラーゼ酵素阻害剤としての使用
|
|
CN110606847A
(zh)
*
|
2019-07-30 |
2019-12-24 |
中国医药集团总公司四川抗菌素工业研究所 |
一种他达拉非顺式中间体的制备方法及其应用
|
|
US11590209B2
(en)
|
2020-01-21 |
2023-02-28 |
Palatin Technologies, Inc. |
Use of bremelanotide in patients with controlled hypertension
|
|
WO2021245192A1
(en)
|
2020-06-04 |
2021-12-09 |
Topadur Pharma Ag |
Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
|
|
EP4656194A1
(en)
|
2023-01-25 |
2025-12-03 |
Aribio Co., Ltd |
Composition for preventing or treating post-traumatic stress disorder, comprising phosphodiesterase type 5 inhibitor as active ingredient
|
|
AU2024220563A1
(en)
|
2023-02-16 |
2025-08-14 |
University Of Rochester |
Improving glymphatic-lymphatic efflux
|
|
CN116715667A
(zh)
*
|
2023-06-20 |
2023-09-08 |
常州制药厂有限公司 |
一种他达拉非新晶型b及其制备方法
|